2024-11-15T13:49:05-05:00 2023-12-31 860839652 ECKELBERG & WIENSHIENK PC 5843 E ORANGE BLOSSOM LANE PHOENIX AZ 850186730 990 2023-01-01 860818253 INTERNATIONAL CANCER ADVOCACY NETWORK INTE 6026180183 27 WEST MORTEN AVENUE PHOENIX AZ 85021 MARCIA K HORN JD PRESIDENT AND CEO 6026180183 2024-11-15 true true DUANE ECKELBERG P00106799 4804231888 2024-11-15 2023 2024-10-15 13:58:12Z ICAN MARCIA K HORN JD 27 WEST MORTEN AVENUE PHOENIX AZ 85021 1813109 false X WWW.ASKICAN.ORG X 1995 AZ ICAN ASSISTS STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AS WELL AS ACCESS TO MOLECULAR PROFILING AND CLINICAL TRIALS. 5 4 1 218 0 1378104 1467491 0 -1317 13201 -18961 -29376 1357826 1451316 290100 300000 0 204274 211957 0 9183 421292 515948 915666 1027905 442160 423411 3351569 3781783 7393 14196 3344176 3767587 X ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE UNITED STATES AND ABROAD. ICAN ANNUALLY AWARDS RESEARCH GRANTS BASED ON SPECIAL EVENT PROCE false false 535000 300000 PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 300,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, THE UNIVERSITY OF PITTSBURGH, AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS, AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2023-2024 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, AND THE PD-L1 AMPLIFIEDS. 214650 PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 20 STATES AND COUNTING); SUPPORTING CO- PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL-FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012. 207979 MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS. 957629 true true false false false false false false false false true false false false true false false false false false false false false false true false false true false true false false false false false false true false true false false false false true false false false true 14 0 1 true false false false false false true true false false false false false false false false X 5 4 false false false false false false false true true false false true true true true true true true true false X X X CHAIR BOARD GOVERNANCE COMMITTEE 6026180183 27 WEST MORTEN AVENUE PHOENIX AZ 85021 SHERRY WEINSTEIN CHAIR-TTEES- 30.00 X X 0 0 0 MARCIA K HORN JD PRESIDENT AN 90.00 X X 172000 0 27531 CATHY DALZELL CHAIR ADIVIS 10.00 X X 0 0 0 CHERYL J HINTZEN-GAINES CHAIR-HONORA 3.00 X X 0 0 0 SIDNEY M ROSEN ESQ FOUNDING CHA 10.00 X X 0 0 0 172000 27531 1 false true false J S HORN 27 W MORTEN AVE PHOENIX AZ 85021 GOVT RELATIONS 152004 1 137286 1330205 302267 1467491 8481 8481 321277 316557 4720 4720 4720 15860 137286 45236 -29376 -29376 1451316 -16175 X 300000 300000 172000 163400 3440 5160 27531 26155 550 826 12426 11805 248 373 1029 1029 13173 13173 290371 290171 200 1329 1329 30917 26451 1717 2749 63624 33290 30334 32747 26197 6550 69882 69882 275 275 4668 1400 3268 DUES AND SEMINARS 2869 2794 75 BOOKS AND SUBSCRIPTIONS 2373 2044 329 PROFESS.COUNCILS DEVELOP. 1471 1471 LICENSES & FEES 1002 965 37 218 218 1027905 957629 61093 9183 1229914 676721 1446769 2451238 305 661505 7986 653794 653519 14290 6802 3351569 3781783 7393 13466 730 7393 14196 X 3344176 3767587 3344176 3767587 3351569 3781783 423411 X false false false X 1148479 987239 971858 1378104 1467491 5953171 1148479 987239 971858 1378104 1467491 5953171 5953171 698 521 912 3327 8481 13939 14560 10010 17160 41730 6008840 0.99070 0.98730 X PART II, LINE 10 GROSS GOLF EVENT PROCEEDS 41,730 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7986 7986 653519 653519 653519 PAYROLL TAXES 730 730 FISTBUMP FUNDRA 77827 77827 GOLF INVITATION 70368 54508 15860 45236 1 148195 132335 15860 45236 45236 -29376 true HEYMACH LAB-MD ANDERSON CANCER CNTR 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 100000 ACTIONABLE MUTATIONS O'CONNOR LAB-CNTR CELLULAR IMMUNO 3400 CIVIC CENTER BLVD BLDG 421 PHILADELPHIA PA 19104 231352685 52500 IMMUNOTHERAPY RESRCH LUNG CANCER RESEARCH FOUNDATION 501 7TH AVE 401 NEW YORK NY 10018 141935776 37500 UCSF GRANT JOHN MINNA LAB-UT SOUTHWESTERN LABS 6000 HARRY HINES BLVD DALLAS TX 75390 756002868 70000 ACTIONABLE MUTATIONS TIMOTHY BURNS LAB-UNIV PITTSBURGH 5117 CENTRE AVE STE 218E LAB 27 PITTSBURGH PA 15213 250965591 40000 ACTIONABLE MUTATIONS 5 SCHEDULE I, PAGE 1, PART I, LINE 2 ICAN HAS AWARDED RESEARCH GRANTS TO THE NAMED LABORATORIES AND INVESTIGATORS. REPRESENTATIVES OF ICAN AWARDEES PROVIDE PERIODIC UPDATES ON THEIR PROGRESS TO ICAN'S CEO AND TO MEMBERS OF THE GRANT COMMITTEE. RESEARCH GRANT FUNDS ARE SOLELY SPENT WITHIN THE UNITED STATES. X X X false false false false false false false false false MARCIA K HORN JD PRESIDENT AND CEO 172000 27531 199531 J S HORN PHD FAMILY MEMBER 152004 INDEPENDNT CONTRACTR false SCHEDULE L, PART V SCH L, PART IV(1)-J.S. HORN, PHD, DIRECTOR, GOVERNMENTAL RELATIONS, FAMILY MEMBER OF BOARD MEMBER X 2 302267 DATE CONTRIBUTED FMV false true false FORM 990 - ORGANIZATION'S MISSION ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE UNITED STATES AND ABROAD. ICAN ANNUALLY AWARDS RESEARCH GRANTS BASED ON SPECIAL EVENT PROCEEDS AND SPONTANEOUS MEMORIAL AND TRIBUTE DONATIONS SUPPORTING OUR INTERNATIONAL RESEARCH CONSORTIUM'S GOAL TO DEFEAT RARE CANCERS SUCH AS EGFR EXON 20, HER2 EXON 20, AND MET ALTERATIONS. ICAN'S OVERARCHING FOCUS IS OUR DETAIL-ORIENTED PATIENT PROGRAM SERVICES AND RESEARCH ADVOCACY SERVICES WORKING CLOSELY WITH PATIENTS, CARE PARTNERS, CLINICIANS, SCIENTISTS, AND INVESTIGATORS WHO SHARE OUR RESEARCH GOALS. SEE ASKICAN.ORG AND UNDER THE ICAN NONPROFIT UMBRELLA: EXON20GROUP.ORG, BIOMARKERCOLLABORATIVE.ORG, METCRUSADERS.ORG, AND PDL1AMPLIFIEDS.ORG. FORM 990, PAGE 2, PART III, LINE 4A PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 300,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, THE UNIVERSITY OF PITTSBURGH, AND THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS, AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2023-2024 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, AND THE PD-L1 AMPLIFIEDS. FORM 990, PAGE 2, PART III, LINE 4B PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 20 STATES AND COUNTING); SUPPORTING CO- PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL-FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012. FORM 990, PAGE 2, PART III, LINE 4C MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF FORM 990 IS PROVIDED TO BOARD MEMBERS FOR THEIR REVIEW BEFORE THE FORM 990 IS FILED. THE CHAIRMAN OF THE BOARD OF TRUSTEES AND THE CHAIRS OF THE GOVERNANCE AND COMPENSATION COMMITTEES REVIEW, WITH ICAN'S CEO, COMMENTS REGARDING DRAFTS OF THE FORM 990. INPUT IS OBTAINED FROM MEMBERS OF ICAN'S INTERNAL AUDIT COMMITTEE AND SPECIAL EVENTS COMMITTEES. AT THE DIRECTION AND APPROVAL OF THE FULL BOARD, A SUBGROUP OF THE ORGANIZATION'S EXECUTIVE OFFICERS THEN COMPLETES ITS FINAL REVIEW, AND THE FORM 990 IS FILED. FORM 990, PAGE 6, PART VI, LINE 12C BOARD MEMBERS ANNUALLY DISCLOSE IN WRITING ALL POTENTIAL OR ACTUAL CONFLICTS OF INTEREST TO THE BOARD GOVERNANCE COMMITTEE. FORM 990, PAGE 6, PART VI, LINE 15A SINCE 2003, THE ORGANIZATION HAS ANNUALLY REVIEWED THE CEO'S COMPENSATION, WITH AN ANALYSIS THAT INCLUDES COMPARISONS TO OTHER CANCER ORGANIZATION CHIEF EXECUTIVE OFFICERS' COMPENSATION AS WELL AS OTHER HEALTH CARE NONPROFIT ORGANIZATION CHIEF EXECUTIVE OFFICERS' SALARIES. SEVERAL YEARS AGO, THE ORGANIZATION BENEFITED FROM AN EXTERNAL ORGANIZATION'S ANALYSIS THAT IS DEVOTED ENTIRELY TO FOR-PROFIT AND NONPROFIT EXECUTIVES' COMPENSATION. THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. FORM 990, PAGE 6, PART VI, LINE 15B THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION'S WEBSITE HAS AN EXTENSIVE BOARD GOVERNANCE SECTION. THE ORGANIZATION'S FORM 990 AS WELL AS ALL BOARD GOVERNANCE DOCUMENTS, INCLUDING CONFLICT OF INTEREST POLICY, WHISTLEBLOWER POLICY, AND DOCUMENTS RETENTION POLICY, ARE AVAILABLE ON ICAN'S WEBSITE (COMPENDIUM OF BOARD POLICIES) AND AT AVAILABLE AT GUIDESTAR/CANDID AS WELL AS CHARITY NAVIGATOR. FORM 990, PART IX, LINE 11G PATIENT SERVICES 110,925 0 0 PATIENT ACCESS/HEALTH EQUITY 177,004 0 0 OUTSIDE SERVICES 2,242 200 0 TOTAL 290,171 200 0 BIOMARKER COLLABORATIVE INC 27 W MORTEN AVE PHOENIX AZ 85021 883107993 SUPPORT WI 501C3 10 INTERNATL CANCER ADVOCACY NETWORK false MET CRUSADERS INC 4524 BLUE MOUNDS TRAIL BLACK EARTH WI 53515 871238935 SUPPORT WI 503C3 7 INTERNATL CANCER ADVOCACY NETWORK false false false false false false false false false false false false false false false false false false false false